Basel, September 7, 2020 — Novartis today announced that high-dose, once-daily Enerzair ® Breezhaler ® (indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) significantly ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Enerzair Breezhaler, the first triple-combination asthma therapy that ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side ...
Novartis has published the full results from the phase 3 IRIDIUM study of its Enerzair Breezhaler in patients with uncontrolled asthma. The results, which were published in The Lancet Respiratory ...
New analysis shows high-dose, once-daily Enerzair Breezhaler cut asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose A high dose of Novartis’ Enerzair Breezhaler ...
The product includes the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU The European Commission (EC) has approved Novartis’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results